REVIEW

Psychosocial interventions for reducing diabetes distress in vulnerable people with type 2 diabetes mellitus: a systematic review and meta-analysis

Anne Sophie Mathiesen¹ Ingrid Egerod² Tonny Jensen¹ Gudrun Kaldan³ Henning Langberg⁴ Thordis Thomsen³

¹Department of Endocrinology, Abdominal Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; ²Intensive Care Unit 4131, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; ³Abdominal Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; ⁴CopenRehab, Section of Social Medicine, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Correspondence: Anne Sophie Mathiesen Department of Endocrinology, Abdominal Centre, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark Tel +45 2790 8669 Fax +45 3545 5213 Email anne.sophie.mathiesen@regionh.dk



Abstract: Diabetes distress (DD) disproportionately affects vulnerable people with type 2 diabetes mellitus and interventions targeting this population are therefore relevant. A systematic review and meta-analysis was performed to assess the evidence for an effect of psychosocial interventions for reducing DD, and, secondly HbA1c, depression, and health-related quality of life in vulnerable people with type 2 diabetes mellitus. Vulnerability encompasses poor glycemic control (HbA1c >7.5%) and at least one additional risk factor for poor diabetes outcomes such as low educational level, comorbidity, and risky lifestyle behavior. The interventions should be theoretically founded and include cognition- or emotion-focused elements. We systematically searched four databases for articles published between January 1995 and March 2018. Eighteen studies testing a variety of psychosocial interventions in 4,066 patients were included. We adhered to the Cochrane methodology and PRISMA guidelines. Review Manager 5.3 was used for data extraction and risk of bias assessment, and Grades of Recommendation, Assessment, Development and Evaluation for assessing the quality of the evidence. Data were pooled using the fixed or random effects method as appropriate. We investigated effects of individual vs group, intensive vs brief interventions, and interventions with and without motivational interviewing in subgroup analyses. To assess the robustness of effect estimates, sensitivity analyses excluding studies with high risk of bias and attrition >20% were conducted. We found low to moderate quality evidence for a significant small effect of psychosocial interventions on DD, and very low to moderate quality evidence for no effect on HbA1c, both outcomes assessed at 3, 6, 12, and 24 months follow-up. The effect on depression was small, while there was no effect on health-related quality of life. Exploratory subgroup analyses suggested that interventions using motivational interviewing and individual interventions were associated with incremental effects on DD. Likewise, intensive interventions were associated with significant reductions in both DD and HbA1c.

Keywords: diabetes distress, HbA1c, meta-analysis, psychosocial interventions, type 2 diabetes, vulnerable populations

Introduction

The daily demands of people living with type 2 diabetes mellitus (T2DM) may increase the risk of diabetes distress (DD).¹ DD is a condition of stressful feelings associated with the challenges of managing diabetes and concerns related to diabetic complications.¹ The prevalence of DD ranges from 18% to 35% in a general population with T2DM,^{2,3} but is substantially higher in ethnic minority subgroups and in hospitalized patients.⁴ DD is associated with a longer duration of diabetes diagnosis, reduced adherence to treatment⁵ and glycemic control⁶ leading to an

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019:12 19–33 **I9** Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019:12 19–33 **I9** Diabetes, Metabolic Syndrome and Obesity: Targets and License by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. by Day Bergy acception of the work are premitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 42 and 5 of our Terms (http://www.dovepress.com/terms.php). elevated risk of diabetic complications.^{5,7,8} Additionally, DD may progress to depression,⁹ potentially leading to risk of premature death.¹⁰ DD is distinct from depression by being far more prevalent¹¹ and directly related to diabetes management.^{11–13} It is particularly relevant to address DD given the high prevalence and association with diabetes management in people with T2DM.¹³

DD disproportionately affects vulnerable people with T2DM.² Vulnerable people are those requiring the utmost care and consideration, and who are often characterized by factors associated with an increased risk of DD,14 such as low educational level, comorbidity,³ and poor glycemic control, which is overrepresented in this population.¹⁵ Likewise, living alone and risky lifestyle behaviors such as smoking, unhealthy diet, and sedentary lifestyle are more often present in people with T2DM suffering severe and prolonged DD.² The clustering of risk factors for DD can increase hormonal stressors, thereby further affecting blood glucose.¹⁶ Indeed, trajectories of DD appear most severe and persistent in vulnerable people with T2DM.² Consequently, consideration of DD specifically in vulnerable people with T2DM is relevant for self-management⁶ and prevention of complications in an already susceptible group.5

In many clinical settings, interventions for reducing DD are not standard care.¹¹ This suggests that caregivers and current health care interventions fail to sufficiently embrace the needs of vulnerable people with T2DM.17 The relationship between DD, self-management, and glycemic control has primarily been described associatively.^{12,18} Hence, the causal pathways among these concepts remain unclear.^{19,20} Nevertheless, we hypothesize that interventions specifically targeted toward reducing DD in vulnerable people with T2DM, might potentially improve glycemic control. Due to the complex psychosocial and pathophysiological factors associated with the increased risk of DD among vulnerable people with T2DM, we contend that interventions including a psychosocial approach might better alleviate DD.²⁰ Recent reviews of interventions for reducing diabetes-related distress focused on effects in general diabetes populations rather than vulnerable populations.^{20,21} Given the susceptibility of vulnerable people with T2DM to increased levels of DD and diabetic complications, the current review therefore focuses specifically on existing evidence for interventions targeting this subgroup of people.^{22,23}

Objective

20

To examine the evidence for an effect of psychosocial interventions vs standard care for reducing DD and HbA1c,

depression, and health-related quality of life (HRQOL) in vulnerable people with T2DM.

Materials and methods

This is a systematic review adhering to Cochrane methodology. The review was registered in PROSPERO (The International Prospective Register of Systematic Reviews) with registration number CRD42018064454 and reported according to the PRISMA guidelines.²⁴

Types of studies

We included parallel group randomized clinical trials (RCTs) assessing DD as either a primary or secondary outcome. Exclusion criteria were as follow: cluster-randomized trials due to the potential lack of sensitivity to individual vulner-ability characteristics,²⁵ cross-over randomized trials, and nonrandomized controlled trials.

Participants

Participants were vulnerable people with type 2 diabetes duration for more than 1 year, ≥ 18 years, and HbA1c > 7.5% (58 mmol/mol) at baseline. Vulnerability was defined as in the included studies, but including at least one or more of the following criteria: low socioeconomic status, low health literacy, Hispanic, African-American or other ethnic origin predisposed to an elevated risk of T2DM,²⁶ comorbidity, or risky lifestyle defined as body mass index >30, sedentary lifestyle, smoking, or alcohol use exceeding 7 units weekly for women and 14 units weekly for men. The vulnerability criteria were informed by recommendations in the PROG-RESS²⁷ PLUS framework, which is an "equity lens" also applied by the Cochrane Collaboration. The PLUS edition includes individual characteristics such as lifestyle behaviors. We excluded studies including both type 2 and type 1 diabetes as no socioeconomic gradient has been described in type 1 diabetes.²⁸

Types of interventions

Psychosocial interventions that were emotion focused and/ or cognition focused and administered person-to-person, in groups, or digitally, by peers, caregivers or health care professionals, either alone or in combination, for reducing DD in vulnerable people with T2DM. Emotion-focused interventions aim to address patients' self-management practices and thereby influence health outcomes,²⁹ while cognition-focused interventions involve education and acquisition of diabetesrelated skill training. The theoretical foundations underlying interventions should be prespecified in the methods section or study protocol. Included interventions could be brief or intensive and delivered in health care or homecare settings.

Controls

Usual care as defined in included studies. If studies had more than one arm, the arm most similar to usual care was selected as the control.

Outcomes

Primary outcome

DD assessed by Problem Areas in Diabetes (PAID)¹ or the Diabetes Distress Scale (DDS) at 3, 6, 12, and 24 months.³² In DDS, mean item scores of 2.0–2.9 indicate moderate distress, and scores >3 indicate clinically important distress requiring intervention.²² For the validated 20-item PAID scale, scores >40 indicate clinically important distress.³³

Secondary outcomes

HbA1c measured at 3, 6, 12, and 24 months follow-up. For studies where follow-up time points did not match exactly, data from the closest time point were included. Depression was measured with validated instruments such as Patient Health Questionnaire (PHQ-9)³⁴ at the longest follow-up. HRQOL was measured with validated instruments or diabetes-specific instruments such as Diabetes Quality of Life¹¹ at the longest follow-up.

Search strategy

We searched PubMed/Medline, EMBASE, CINAHL, and PsycINFO using different combinations in a search matrix based on the PICO (patient, intervention, comparison, outcomes) format sans comparisons. The latest search was performed on June 19, 2017 supplemented with ongoing alerts from the databases when new studies within the search matrix were published (Table 1). We ended inclusion on March 31, 2018. We included studies published in English from 1995 and onward. The temporal limitation was chosen to coincide with the development of the PAID instrument in 1995.¹ Gray literature and reference lists of included studies were screened. Reference lists of reviews and meta-analyses retrieved from the searches were also screened. We screened the search results in Covidence Systematic Review Software.³⁵

Identification of relevant studies

The first and last authors (ASM, TT) independently screened titles and abstracts for eligibility using the following order of importance: RCT, T2DM, DD measured by DDS or PAID, and vulnerable population. Thus, the first "no" was stated as reason for exclusion. We were not masked to authors or journals during the screening process.

Data extraction and management

Characteristics of the included studies were individually extracted by ASM and GK and included the following: author, title, and year published; Methods: design including number of trial groups, country, and publication date; Participants: number at baseline and follow-up, vulnerability criteria, mean age, mean duration of T2DM, type of treatment (lifestyle, tablets, insulin), comorbidity, and diabetes-related complications. Intervention: setting, intensity, delivery, deliverer involved and training/quality control.

Risk of bias in individual studies

ASM, GK, and TT independently assessed risk of bias in included studies using the Cochrane Collaboration's Risk of Bias Tool.³⁶ Due to the nature of the intervention, blinding of participants and staff was not considered feasible. We considered DD, HRQOL, and depression at high risk of detection bias due to lack of blinding, whereas HbA1was considered at low risk. Disagreements were discussed

Table	L	Literature	search
-------	---	------------	--------

#	Keywords	Inclusion
1	Patients	Type 2 diabetes; type 2 diabetes mellitus; diabetes, type 2; T2DM; diabetes T2; diabetes
		mellitus; vulnerable population [MeSH]; diabetes mellitus, type 2 [MeSH]
2	Interventions	Psychological intervention; psychological feedback; psychotherapy; psychological techniques;
		digital intervention; internet; cognitive focused intervention; cognitive intervention; cognitive
		therapy; cognitive behavior therapy; behavioral intervention; emotional focused intervention;
		cognitive behavior therapies [MeSH term]; feedback, psychological
3	Outcomes	Diabetes distress; distress; diabetes-related distress; problem areas in diabetes; Diabetes
		distress scale; PAID; DDS; HbA1c; hb A1c; glycosylated hemoglobin A; medication adherence
		[MeSH]; health related quality of life; quality of life [MeSH]; patient compliance [MeSH]
		# I AND 2 AND 3.

among authors until consensus was reached. We attempted to retrieve protocols in clinicaltrials.gov or published protocols for all included studies to assess potential selective reporting. In studies with missing information, the authors were contacted.

Data analysis

Meta-analyses were performed using available case analysis and the fixed or random effects method as appropriate. The meta-analyses were pairwise and were weighted by the inverse variance. We assessed the degree of heterogeneity using the I^2 statistic which measures the percentage of variability in effect estimates due to heterogeneity rather than sampling error.²⁵ If $I^2 > 60\%$, we used the random effects method. We used the Mean Difference (MD) with 95% CI to assess effects of interventions on continuous outcomes. If different instruments were used, we used the Standardized Mean Difference (SMD). On DD and HbA1c, betweengroups differences at 3, 6, 12, and 24 months follow-up were extracted. On depression and HRQOL, between-groups differences at longest follow-up were used. To increase transparency, risk of bias ratings and meta-analyses were displayed together. We investigated the risk of publication bias using funnel plots,³⁷ and data analysis was conducted with Review Manager 5.3.

Subgroup analysis

The subgroup analyses are moderator analyses that explore effect heterogeneity. Results from subgroup analyses should therefore be interpreted cautiously.²⁵ The following exploratory subgroup analyses were planned: 1) effect of brief (≤ 4 sessions) vs intensive (>4 sessions) interventions, 2) group vs individual interventions, and 3) motivational interviewing vs other interventions, all on DD and HbA1c at the longest follow-up. The exponential increase in diabetes-related health care expenditures makes it relevant to investigate the effect of less time-consuming interventions³⁸ such as brief and group interventions.

Motivational interviewing may potentially be associated with greater reductions in DD and HbA1c than interventions not including motivational interviewing in people with both type 1 and type 2 diabetes.²¹ It is relevant to explore whether this is also the case when focusing specifically on vulnerable people with T2DM.

Sensitivity analysis

22

We planned to do two sensitivity analyses of the robustness of the effect estimate for the primary outcome DD: 1) excluding studies with high risk of bias (minimum one high risk of bias rating) and 2) excluding studies with high attrition ($\geq 20\%$).

Quality of evidence

We assessed the overall quality of the evidence for the primary outcome DD and the secondary outcomes HbA1c, depression, and HRQOL using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE). This involved consideration of risk of bias, indirectness, inconsistency, imprecision, and publication bias. The quality of the evidence was rated as high, moderate, low, or very low.³⁹ Two authors, ASM and TT, evaluated the quality of the evidence using GRADEpro GDT. Potential disagreements were solved by an arbiter (IE or TJ).

Results

The search yielded 5,035 potentially relevant studies. Of these, 4,721 were obviously irrelevant, leaving 314 studies that were retrieved for full-text assessment. In total, 18 RCTs involving initial recruitment of 4,066 participants were included. Thirteen studies were protocols for "ongoing studies". Studies were primarily excluded due to not measuring DD, wrong design or intervention (Figure 1).

Characteristics of included studies

Sample sizes ranged from 47 to 623.40,41 Sixteen studies originated from the United States with a concentration of studies from deprived areas in Detroit^{42,43} and Boston.^{44,45} One study was conducted in Germany⁴⁶ and one in India.⁴⁷ Hospital settings were represented in 5 studies and community settings in 13. The studies were published in 2004–2017. Participants were primarily from socioeconomically deprived inner-city areas. Nine studies uniquely included patients from Hispanic,48-51 African American,42,43,52,53 or Hawaiian or Samoan origin.⁴⁰ In the remaining studies, participants fulfilled our vulnerability criteria primarily due to a high degree of obesity, comorbidity, and/or low educational level (Table 2). At baseline, mean age was 56±4 and mean duration of T2DM was 11±2.5 years. DD was measured with DDS in two studies^{50,54} and with PAID in 16 studies. Baseline mean DD measured by the 20-item PAID scale was 39±10.8. The five-item short version of PAID was used in three studies. 42,47,49 Mean HbA1c at baseline was 8.7% (72±7.7 mmol/mol).

Interventions

The interventions included combined cognition- and emotion-focused interventions: social support, primarily support groups, some with culturally sensitive elements^{40,43,48,50} in



Figure I PRISMA.

Source: From Mohen D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 6(6):e1000097. doi:10.1371/journal.pubmed1000097. For more information, visit www.prisma-statement.org.

combination with decision support tools,⁴² conversation maps,^{41,45} coaching,⁵⁵ coping skills training and stress management,^{49,53} empowerment training^{47,56} and social and psychological training.⁴⁶ One study provided a telephone intervention for both the person with T2DM and spouse addressing diabetes-related conflict management with collaborative problem-solving techniques.⁵⁴ Another study involved a family member in supporting the patient using the SMART (Specific, Measurable, Attainable, Relevant and Time-bound) goal approach for behavior change with regard to healthy eating, physical activity, and management of diabetes-related distress.⁵⁰ All interventions included elements of diabetes self-management education of varying intensity.^{52,57}

Standard care intervention

Eleven studies provided enhanced standard care of varying intensity. One study sent a monthly reminder via postcard

for 3 months,⁴⁰ one sent a monthly report on diabetes goals and status.⁵² Four studies provided two diabetes self-management education sessions lasting 75 minutes by telephone,⁵⁴ one 2-hour or four 1-hour group sessions.^{45,49,57} One study provided a 90-minute introduction to a print version of a web decision support tool and two follow-up telephone calls,42 one offered free lab tests and consultations,⁴⁷ telephone contact every second week,⁴⁴ another delivered ten diabetes education group sessions⁵³ or ten biweekly sessions of 90 minutes duration focusing on acquisition of standardized diabetes knowledge.⁴⁶ Five studies delivered standard treatment, described as general information on diabetes management provided by a health care professional every 3-4 months. Three studies had a wait-list control design,43,50,55 and three studies delivered an intervention to all participants prior to randomization. These interventions entailed two telephone calls of 75 minutes

year, country(n)at final follow- baseline(moul) baselinedistress, baselinecountryup $(\%)$ μ μ Anderson 310 20 $7.6\% (60)$ 28 (PAID)det al, 2 2009, uSA 134 10 $8.4\% (68)$ 34 (PAID)Beverly et 134 10 $8.4\% (68)$ 34 (PAID)al, 4 2013, uSA 124 10 $8.4\% (68)$ 37 (PAID)al, 2 2010, uSA 134 100 $8.4\% (68)$ 37 (PAID)al, 2 2013, uSA 545 23 $9.0\% (75)$ 29 (PAID)al, 2 2013, uSA 545 23 $9.0\% (75)$ 23 (PAID)al, 2 2013, uSA 186 6 $8.2\% (66)$ 35 (PAID)al, 2 2014, uSA 100 $8.3\% (67)$ 31 (PAID)et al, 2 2014, uSA 47 24 10.0% 34 (PAID)et al, 2 2014, uSA 47 24 $9.0\% (75)$ 34 (PAID)et al, 2 2014, uSA 47 24 10.0% 34 (PAID)et al, 2 2014, uSA 47 24 $9.0\% (75)$ 34 (PAID)et al, 2 2014, uSA 47 24 $9.0\% (75)$ 34 (PAID)et al, 2 2014, uSA 47 24 $9.0\% (75)$ 34 (PAID)et al, 2 2014, uSA 47 24 $9.0\% (75)$ 34 (PAID)et al, 2 2014, uSA 47 24 $9.0\% (75)$ 34 (PAID)et al, 2 2014, uSA 47 24 $9.$	at final (m) follow- mo up bas (%) 7.6' 20 7.6' 20 20 20 7.6' 20 8.4' 23 9.0' 6 8.2'	mol/ mol/ eline mol/ eline % (60) % % (66) % % (75) %	distress, baseline (Scale) 28 (PAID) 34 (PAID) 57 (PAID) 29 (PAID)	criteria Low socioeconomic African American (AA) BMI 34	T2DM (years)	Age		care		up time point
country follow- up mol) at baseline baseline (s,s) baseline (s,s)<	follow- up mo up 20 20 7.6% 20 2.6% 20 2.6% 20 2.6% 20 2.6% 20 2.6% 20 2.6% 20 2.6% 20 2.6% 23 9.0% 6 8.2% 6 8.2%	k (75) k (66) 1) at 1 eline (66) k (60) 2 k (66) k (75) 1 1	Scale) (Scale) 28 (PAID) 34 (PAID) 57 (PAID) 29 (PAID)	Low socioeconomic African American (AA) BMI 34	(years)					point
up up userine Care Anderson 310 20 7.6% (60) 28 (PAID) et al. ³² 2009, USA 310 20 7.6% (60) 28 (PAID) Beverly et 134 10 8.4% (68) 34 (PAID) al. ⁴⁵ 2013, USA 134 10 8.4% (66) 57 (PAID) al. ⁴⁵ 2010, USA 28 8.2% (66) 57 (PAID) al. ⁴⁵ 2013, USA 23 9.0% (75) 29 (PAID) al. ⁴⁵ 2013, USA 545 23 9.0% (75) 29 (PAID) al. ⁴⁵ 2014, USA 109 28 8.2% (66) 35 (PAID) al. ⁴⁵ 2014, USA 188 6 8.2% (66) 35 (PAID) al. ⁴⁵ 2014, USA 10 8.3% (67) 51 (PAID) al. ⁴⁵ 2014, USA 47 24 10.0% 34 (PAID) al. ⁴⁷ 2017, India 11 10.0% 31 (PAID) 31 (PAID) al. ⁴⁷ 2017, India 1 1 33 (PAID) 34 (PAID) al. ⁴⁷ 2017, India 1 1 </th <th>up up Das 20 7.69 26 20 20 7.69 20 20 8.49 23 23 9.09 6 8.23 9.09</th> <th>% (50) % % (66) % % (75) %</th> <th>(Scale) 28 (PAID) 57 (PAID) 29 (PAID)</th> <th>Low socioeconomic African American (AA) BMI 34</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>()</th>	up up Das 20 7.69 26 20 20 7.69 20 20 8.49 23 23 9.09 6 8.23 9.09	% (50) % % (66) % % (75) %	(Scale) 28 (PAID) 57 (PAID) 29 (PAID)	Low socioeconomic African American (AA) BMI 34						()
Anderson 310 20 7.6% (60) 28 (PAID) et al. ³² 2009, USA 134 10 8.4% (60) 28 (PAID) Beverly et 134 10 8.4% (60) 34 (PAID) al. ⁴ 2013, USA 134 10 8.4% (65) 57 (PAID) al. ⁴ 2013, USA 109 28 8.2% (66) 57 (PAID) al. ⁴ 2013, USA 545 23 9.0% (75) 29 (PAID) al. ⁴ 2013, USA 545 23 9.0% (75) 29 (PAID) al. ⁴ 2013, USA 188 6 8.2% (66) 35 (PAID) al. ⁴ 2014, USA 188 10 8.3% (67) 51 (PAID) al. ⁴ 2014, USA 10 8.3% (67) 51 (PAID) al. ⁴ 2014, USA 47 24 10.0% 34 (PAID) al. ⁴ 2017, Usa 91 25 9.3% (78) 10 (PAID) al. ⁴ 2017, Udia 91 0.0% 33 (PAID) 34 (PAID) al. ⁴ 2017, Udia 91 0.0% 34 (PAID) 34 (PAID) <t< th=""><th>20 7.6³ 10 8.4³ 28 8.2³ 23 9.0⁹ 6 8.2⁹</th><th>% (66) % (66) % (75)</th><th>28 (PAID) 34 (PAID) 57 (PAID) 29 (PAID)</th><th>Low socioeconomic African American (AA) BMI 34</th><th></th><th></th><th></th><th></th><th></th><th>(montus)</th></t<>	20 7.6 ³ 10 8.4 ³ 28 8.2 ³ 23 9.0 ⁹ 6 8.2 ⁹	% (66) % (66) % (75)	28 (PAID) 34 (PAID) 57 (PAID) 29 (PAID)	Low socioeconomic African American (AA) BMI 34						(montus)
et al. ³² 2009, USA I34 I0 8.4% (68) 34 (PAID) Bevery et al. ⁴⁵ 2013, USA 134 10 8.4% (68) 34 (PAID) al. ⁴⁵ 2013, USA 109 28 8.2% (66) 57 (PAID) al. ⁹³ 2010, USA 545 23 9.0% (75) 29 (PAID) al. ⁹³ 2010, USA 545 23 9.0% (75) 29 (PAID) al. ⁹¹ 2013, USA 545 23 9.0% (75) 29 (PAID) al. ⁹¹ 2013, USA 186 6 8.2% (67) 31 (PAID) Aleister et al. ⁹¹ 2014, USA 10 8.3% (67) 31 (PAID) al. ⁹¹ 2014, USA 9.3% (78) 10 (PAID) al. ⁹¹ 2017, India 9.1 25 9.3% (78) short) Aleinman et al. ⁹¹ 2017, India 1 10.0% 34 (PAID) Aleinman et al. ⁹¹ 2017, India 9.3% (78) 10 (PAID) Aleinman et al. ⁹¹ 2017, India 1 1 10 (0%	10 8.49 28 8.29 23 9.09 6 8.29	% (66) % (75)	34 (PAID) 57 (PAID) 29 (PAID)	socioeconomic African American (AA) BMI 34	8	56	One monthly	Mailed	HbA Ic,	24
USA 134 10 8.4% (68) 34 (PAID) Bevery et 134 10 8.4% (68) 34 (PAID) usA 134 10 8.4% (68) 34 (PAID) USA D'Eramo et 109 28 8.2% (66) 57 (PAID) al, ⁴³ 2010, USA 545 23 9.0% (75) 29 (PAID) al, ⁴¹ 2013, USA 545 23 9.0% (75) 29 (PAID) al, ⁴¹ 2013, USA 545 23 9.0% (75) 29 (PAID) al, ⁴¹ 2013, USA 186 6 8.2% (67) 51 (PAID) al, ⁴² 2014, USA 10 23% (67) 51 (PAID) al, ⁴² 2014, USA 10 23% (67) 51 (PAID) al, ⁴² 2017, USA 1 10.0% 34 (PAID) al, ⁴² 2017, USA 1 0 33 (PAID) al, ⁴² 2014, USA 1 1 1 1 al, ⁴³ 2017, UIA 1 1 1 1 1	10 8.49 28 8.29 23 9.09 6 8.29	% (66) % (75)	34 (PAID) 57 (PAID) 29 (PAID)	African American (AA) BMI 34			phone call	reports on	PAID,	
Bevery et al, ⁴ 2013, USA 134 10 8.4% (68) 34 (PAID) D'Framo et USA 109 28 8.2% (66) 57 (PAID) al, ¹³ 2010, USA 109 28 8.2% (66) 57 (PAID) al, ¹³ 2010, USA 545 23 9.0% (75) 29 (PAID) al, ¹³ 2013, USA 545 23 9.0% (75) 29 (PAID) al, ¹⁴ 2013, USA 545 23 9.0% (75) 29 (PAID) Heisler et USA 188 6 8.2% (66) 35 (PAID) Heisler et USA 188 6 8.3% (67) 29 (PAID) al, ⁴ 2014, USA 10 8.3% (67) 51 (PAID) Dig et al, ⁴⁶ 7 24 (86) 34 (PAID) 2016, USA 91 25 9.3% (78) 51 (PAID) Alfernman et al, ⁴⁷ 2017, India 91 25 9.3% (78) 54 (PAID) Alfernman et al, ⁴⁷ 2017, India 91 25 9.3% (78) 54 (PAID) Alfernman et al, ⁴⁷ 2017, India 91 9.3% (78) 9.3%	10 8.4% 28 8.2% 23 9.0% 6 8.2%	% (68) % (66) % (75)	34 (PAID) 57 (PAID) 29 (PAID)	American (AA) BMI 34			from DSM	diabetes	PHQ-9	
Beveryet 134 10 8.4% (63) 34 (PAID) ai,* 2013, USA DFramo et 109 28 8.2% (66) 57 (PAID) ai,* 2010, USA 23 9.0% (75) 29 (PAID) 23 29 (PAID) ai,* 2013, USA 545 23 9.0% (75) 29 (PAID) ai,* 2013, USA 6 8.2% (66) 35 (PAID) Heister et 188 6 8.2% (66) 35 (PAID) ai,* 2013, USA 188 6 8.2% (66) 35 (PAID) ai,* 2014, USA 188 6 8.3% (67) 51 (PAID) ai,* 2014, USA 10 8.3% (67) 51 (PAID) Atmanns 186 10 8.3% (67) 51 (PAID) Atmanns 186 10 8.3% (78) 34 (PAID) Atmanns 186 10 8.3% (78) 34 (PAID) Atmanns 19 25 9.3% (78) 10 (PAID) Atmanns 157 1 0.3% (78) 10 (PAID) Atmanns	10 8.4% 28 8.2% 23 9.0% 6 8.2%	% (66) % (68) % (75) %	34 (PAID) 57 (PAID) 29 (PAID)	BMI 34			consultant	status		
a!,* 2013, USA 109 28 8.2% (66) 57 (PAID) DFramo et USA 109 28 8.2% (66) 57 (PAID) a!,* 2010, USA 545 23 9.0% (75) 29 (PAID) a!,* 2013, USA 545 23 9.0% (75) 29 (PAID) a!,* 2013, USA 6 8.2% (66) 35 (PAID) a!,* 2013, USA 188 6 8.2% (67) 29 (PAID) a!,* 2014, USA 10 8.3% (67) 51 (PAID) Ing et al,*0 47 24 10.0% 34 (PAID) Ing et al,*0 47 24 10.0% 34 (PAID) Ing et al,*0 47 25 9.3% (78) 34 (PAID) 2016, USA 91 25 9.3% (78) 10 (PAID) a!,*0 2017, India 157 1 10.0% 34 (PAID) a!,*0 2017, USA 91 010% 34 (PAID) 34 (PAID)	28 8.2 ³ 23 9.0 ³ 8.2 ³	% (66)	57 (PAID) 29 (PAID)		13	59	Conversation	Sessions	HbA Ic,	3, 6, 12
USA USA 57 (PAID) at ³³ 2010, USA 109 28 8.2% (66) 57 (PAID) at ³³ 2010, USA 545 23 9.0% (75) 29 (PAID) at ³¹ 2013, USA 545 23 9.0% (75) 29 (PAID) at ³¹ 2013, USA 6 8.2% (66) 35 (PAID) Heisler et 188 6 8.2% (66) 35 (PAID) at ³¹ 2013, USA 188 6 8.2% (66) 34 (PAID) at ³² 2014, USA 47 24 10.0% 34 (PAID) Ing et al, ⁴⁶ 91 25 9.3% (78) 10 (PAID) at ⁴⁷ 2017, India 91 25 9.3% (78) 10 (PAID) at ⁴⁷ 2017, India 1 10.0% 14 (DDS) at ⁴⁹ 2017, USA 1 1 10.0% 14 (DDS)	28 8.2 ⁹ 23 9.0 ⁹ 6 8.2 ⁹	% (66) % (75)	57 (PAID) 29 (PAID)				map group	focusing on	PAID,	
D'Framo et 109 28 8.2% (66) 57 (PAID) al, ³³ 2010, USA 8.2% (66) 57 (PAID) dai, ³¹ 2013, USA 9.0% (75) 29 (PAID) al, ³¹ 2013, USA 8.2% (66) 35 (PAID) al, ³¹ 2013, USA 8.2% (66) 35 (PAID) Heisler et 188 6 8.2% (66) 35 (PAID) al, ⁴¹ 2014, USA 188 6 8.2% (66) 35 (PAID) Heisler et 188 6 8.3% (67) 29 (PAID) al, ⁴² 2014, USA 47 24 10.0% 34 (PAID) Aleinman et 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 157 1 10.0% 14 (DDS) Al, ⁴⁷ 2017, India 157 1 10.0% 14 (DDS) Al, ⁴⁷ 2017, India 157 1 10.0% 14 (DDS) Al, ⁴⁸ 2017, USA 1 1 1 10.0%	28 8.2 ⁹ 23 9.0 ⁹ 6 8.2 ⁹	% (66) % (75)	57 (PAID) 29 (PAID)				sessions	DSME	DQOL	
at ³³ 2010, USA 545 23 9.0% (75) 29 (PAID) at ³¹ 2013, USA 545 23 9.0% (75) 29 (PAID) at ³¹ 2013, USA 6 8.2% (66) 35 (PAID) Heisler et 188 6 8.2% (66) 35 (PAID) at ³¹ 2013, USA 188 6 8.2% (66) 35 (PAID) at ⁴² 2014, USA 188 10 8.3% (67) 51 (PAID) at ⁴² 2012, Germany 47 24 10.0% 34 (PAID) Ing et at ⁴⁶ 91 25 9.3% (78) 10 (PAID) at ⁴⁷ 2017, India 91 25 9.3% (78) 10 (PAID) at ⁴⁷ 2017, India 1 10.0% 14 (DDS) at ⁴⁸ 2017, USA 1 10.0% 14 (DDS)	23 9.0%	% (75)	29 (PAID)	Low	NR	48	Coping skill	Ten 2-hour	HbA Ic,	12
USA 545 23 9.0% (75) 29 (PAID) al, ^{s1} 2013, USA 545 23 9.0% (75) 29 (PAID) al, ^{s1} 2013, USA 6 8.2% (66) 35 (PAID) Hersler et 188 6 8.2% (66) 35 (PAID) al, ^{s2} 2014, USA 188 6 8.3% (67) 51 (PAID) et al, ⁴⁶ 2012, Germany 10 8.3% (67) 51 (PAID) ing et al, ⁴⁰ 47 24 10.0% 34 (PAID) lng et al, ⁴⁰ 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 1 10.0% 14 (DDS) al, ⁴⁰ 2017, USA 1 10.0% 14 (DDS)	23 9.09 6 8.29	% (75)	29 (PAID)	socioeconomic			training group	group	PAID, SF36	
Gabbay et 545 23 9.0% (75) 29 (PAID) al, ^{s1} 2013, USA B 8.2% (66) 35 (PAID) Heisler et 188 6 8.2% (66) 35 (PAID) al, ^{s1} 2014, USA B 8.3% (67) 51 (PAID) al, ^{s2} 2014, USA 10 8.3% (67) 51 (PAID) et al, ⁴⁶ 2012, Germany 47 24 10.0% 34 (PAID) Ing et al, ⁴⁰ 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 91 25 9.3% (78) 10 (PAID) Aleinman et 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 1 10.0% 14 (DDS) Aleinman et 91 25 9.3% (78) 14 (DDS) al, ⁶⁰ 2017, USA 1 10.0% 14 (DDS) 14 (DDS)	23 9.0° 6 8.2°	% (75)	29 (PAID)	black women			sessions	sessions		
Gabbay et al, ^{s1} 2013, USA 545 23 9.0% (75) 29 (PAID) al, ^{s1} 2013, USA Heisler et 188 6 8.2% (66) 35 (PAID) Heisler et 188 6 8.3% (67) 51 (PAID) usA 186 10 8.3% (67) 51 (PAID) us al, ⁴ 2012, Germany 47 24 8.3% (67) 51 (PAID) hg et al, ⁴⁶ 2012, Germany 91 23 9.3% (78) 34 (PAID) hg et al, ⁴⁰ 2017, hd et al, ⁴⁰ 2017, hd at, ⁴⁰ 2017, 1 10.0% 14 (DDS)	23 9.0° 6 8.2°	% (75)	29 (PAID)					providing		
Gabbay et 545 23 9.0% (75) 29 (PAID) al,°1 2013, USA B8 6 8.2% (66) 35 (PAID) Heisler et 188 6 8.2% (66) 35 (PAID) al,°1 2014, USA 8 8.2% (66) 35 (PAID) al,°2 2014, USA 188 6 8.3% (67) 51 (PAID) dermanns 186 10 8.3% (67) 51 (PAID) dermany 47 24 10.0% 34 (PAID) Dig et al,** 47 24 10.0% 34 (PAID) 2016, USA 91 25 9.3% (78) 10 (PAID) al,*7 2017, India 91 25 9.3% (78) 10 (PAID) al,*7 2017, India 1 10.0% 14 (DDS) al,*0 2017, USA 1 1 10.0% 14 (DDS)	23 9.0% 6 8.2%	({/) %	29 (PAID)		!		-			
at, st 2013, USA 188 6 8.2% (66) 35 (PAID) Heisler et 188 6 8.2% (66) 35 (PAID) at, st 2014, USA 188 6 8.3% (67) 51 (PAID) hermanns 186 10 8.3% (67) 51 (PAID) et at, st 2012, Germany 47 24 10.0% 34 (PAID) Ing et at, st 91 25 9.3% (78) 10 (PAID) at, st 2017, India 91 25 9.3% (78) 10 (PAID) at, st 2017, India 1 10.0% 14 (DDS) at, st 2017, USA 1 10.0% 14 (DDS)	6 8.23			Socioeconomic	NR	58	Individual	Usual care	HbA1c,	24
USA USA 82% (66) 35 (PAID) Heisler et 188 6 8.2% (66) 35 (PAID) al, ⁴² 2014, 83% (67) 51 (PAID) 8.3% (67) 51 (PAID) USA 10 8.3% (67) 51 (PAID) 8.3% (57) 51 (PAID) Hermanns 186 10 8.3% (57) 51 (PAID) Ing et al, ⁴⁰ 47 24 10.0% 34 (PAID) 2016, USA 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, 1 25 9.3% (78) 10 (PAID) India 157 1 10.0% 14 (DDS) al, ⁸⁰ 2017, 1 1 10.0% 14 (DDS) uSA USA 1 10.0% 14 (DDS)	6 8.23			deprived			sessions with		PAID,	
Heisler et 188 6 8.2% (66) 35 (PAID) al, ⁴² 2014, USA 188 10 8.3% (67) 51 (PAID) Hermanns 186 10 8.3% (67) 51 (PAID) Hermanns 186 10 8.3% (67) 51 (PAID) Germany 47 24 10.0% 34 (PAID) Jng et al, ⁴⁰ 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 91 25 9.3% (78) 10 (PAID) Aleinman et 91 25 9.3% (78) short) India 157 1 10.0% short) MCEwen et 157 1 10.0% short) USA USA 1 10.0% short) <td>6 8.2</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>nurse trained</td> <td></td> <td>C-DES</td> <td></td>	6 8.2						nurse trained		C-DES	
Heisler et 188 6 8.2% (66) 35 (PAID) al, ⁴² 2014, USA 186 10 8.3% (67) 51 (PAID) Hermanns 186 10 8.3% (67) 51 (PAID) Hermanns 186 10 8.3% (67) 51 (PAID) Germany 24 10.0% 34 (PAID) Jng et al, ⁴⁶ 47 24 10.0% 34 (PAID) 2016, USA 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 157 1 10.0% 14 (DDS) Al, ⁵⁰ 2017, USA 1 10.0% 14 (DDS)	6 8.29						in MI			
al, ⁴² 2014, USA 186 10 8.3% (67) 51 (PAID) Hermanns 186 10 8.3% (67) 51 (PAID) et al, ⁴⁶ 2012, Germany 47 24 10.0% 34 (PAID) Ing et al, ⁴⁰ 47 24 10.0% 34 (PAID) 2016, USA 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 1 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 1 10.0% 14 (DDS) al, ⁵⁰ 2017, USA 1 10.0% 14 (DDS)		% (66)	35 (PAID)	Low income	6	R	Idecide web	Idecide print	HbAIc and	e
USA USA Hermanns 186 10 8.3% (67) 51 (PAID) et al,* 2012, Germany 8.3% (67) 51 (PAID) 10.0% Jng et al,* 2014, USA 8.3% (67) 34 (PAID) Ing et al,* 8.7 2.4 10.0% 34 (PAID) 2016, USA 9.1 2.4 10.0% 34 (PAID) Affeinman et 91 2.5 9.3% (78) 10 (PAID) al,*7 2017, India 9.1 2.5 9.3% (78) 10 (PAID) Affeinman et 91 2.5 9.3% (78) 10 (PAID) al,*7 2017, India 1 10.0% 14 (DDS) al,*0 2017, USA 1 10.0% 14 (DDS)				Latino and AA			decision	version	PAID	
Hermans 186 10 8.3% (67) 51 (PAID) et al, ⁴⁶ 2012, 8.3% (67) 51 (PAID) Germany 47 24 0.0% 34 (PAID) Ing et al, ⁴⁰ 47 24 10.0% 34 (PAID) 2016, USA 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, 1 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, 1 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, 1 25 9.3% (78) 10 (PAID) al, ⁴⁵ 2017, 1 10.0% 14 (DDS) al, ⁴⁵ 2017, 1 10.0% 14 (DDS)							support tool.			
et al,** 2012, 34 (PAID) Germany 47 24 10.0% 34 (PAID) Ing et al,** 91 25 9.3% (78) 10 (PAID) 2016, USA 91 25 9.3% (78) 10 (PAID) al,** 2017, 1 25 9.3% (78) 10 (PAID) India 11 25 9.3% (78) 10 (PAID) al,** 2017, 1 25 9.3% (78) 10 (PAID) Antise 1 21 25 23% (78) 10 (PAID) al,** 2017, 1 10.0% 14 (DDS) 14 (DDS) al,** 2017, 1 10.0% 14 (DDS) 24,*** USA USA 26 26 26 26 26	10 8.39	% (67)	51 (PAID)	Comorbidity	4	63	Skill training,	Sessions	HbA Ic,	6
Germany 47 24 10.0% 34 (PAID) Ing et al, ⁴⁰ 47 24 10.0% 34 (PAID) 2016, USA 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 157 1 10.0% 14 (DDS) Al, ⁴⁰ 2017, USA 157 1 10.0% 14 (DDS)							social and	focusing on	PAID; SFI2	
Ing et al, ⁴⁰ 47 24 10.0% 34 (PAID) 2016, USA 86) 34 (PAID) 86) 10 (PAID) Kleinman et 91 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 1 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 1 25 9.3% (78) 10 (PAID) al, ⁴⁷ 2017, India 1 10 (PAID) 10 (PAID) Acceven et 157 1 10.0% 14 (DDS) al, ⁵⁰ 2017, USA 1 10.0% 14 (DDS)							psychological	DSME		
Ing et al, ⁴⁰ 47 24 10.0% 34 (PAID) 2016, USA 91 25 9.3% (78) 10 (PAID Kleinman et 91 25 9.3% (78) 10 (PAID al, ⁴⁷ 2017, 91 25 9.3% (78) 10 (PAID al, ⁴⁷ 2017, 1 25 9.3% (78) 10 (PAID al, ⁴⁰ 2017, 1 25 9.3% (78) 10 (PAID al, ⁴⁰ 2017, 1 10.0% 14 (DDS) al, ⁵⁰ 2017, 1 10.0% 14 (DDS) USA USA 1 10.0% 14 (DDS)							support			
2016, USA 91 25 9.3% (78) 10 (PAID Kleinman et 91 25 9.3% (78) 10 (PAID al, ⁴⁷ 2017, 1 25 9.3% (78) 10 (PAID India MCEven et 157 1 10.0% 14 (DDS) al, ⁵⁰ 2017, al, ⁵⁰ 2017, 1 10.0% 14 (DDS) USA USA 1 10.0% 14 (DDS)	24 10.0	» %	34 (PAID)	Hawaiian,	NR		Social support	Postcard	HbAIc and	6
Kleinman et al. ⁴⁷ 2017, India 91 25 9.3% (78) 10 (PAID short) India 1 10 10 (PAID short) 10 (PAID short) India 1	(86)			Samoan		55	group sessions	reminder	PAID	
Mcmman C	75 939	X (78)			ala	48	Empowerment	Free	НЬА ГС	3 6
India Lindia Meteore et 157 1 10.0% 14 (DDS) al,º 2017, (86)	<u>, , , , , , , , , , , , , , , , , , , </u>	, (0.) %	short)	educational		2	ann for	consultations		5 î
McEwen et 157 1 10.0% 14 (DDS) al, ⁵⁰ 2017, (86) (86) 14 (DDS) USA 1 10.0% 14 (DDS)		-	6	level			Datients	and lab tests		
al, ^{so} 2017, (86) USA	1	%	14 (DDS)	Mexican	12	54	Dyad of	Waitlist	HbA Ic and	6, 9
USA	(86)			American			patient with	group	DDS	
				adults BMI 33			supportive			
							family member			
McMahon 101 1 9.6% (81) 26 (PAID)	I 9.6%	% (81)	26 (PAID)	Veteran Affairs	NR	60	Online care	Web training	HbA1c and	12
et al,44 2012, 115 A				Department,			group		PAID	
										(Cational)

Author, year,	Total			• • • -							
year,		Attrition	HbAIc	Diabetes	Vulnerability	Duration,	Mean	Intervention	Standard	Outcomes	Follow-
	(u)	at final	(Iomm)	distress,	criteria	T2DM	Age		care		up time
country		follow-	mol) at	baseline		(years)					point
		dn	baseline	(Scale)							(months)
Spencer et	164	18	8.6% (70)	13 PAID	Low income,	8	53	Culturally	Delayed	HbA Ic and	6
al,43 2011,				at log	AA and Latino			tailored group	control	PAID	
USA				scale				intervention	group		
Sperl-Hillen	623	0 (ITT)	8.3% (67)	30 (PAID)	Low	NR	NR	Conversation	Standard	HbA Ic,	12
et al,4' 2013,					educational			map	care	PAID, and	
USA					status					PHQ-9	
Tang et al, ⁵⁶	382	0 (TTT)	9.3% (78)	NR	Comorbidity	NR	54	MI web-based	Standard	HbA Ic,	6
2013, USA								intervention	care	DDS, and	
										PHQ-9	
Trief et al, ⁵⁴	186	0 (ITT)	9.1% (76)	2.3 (DDS)	65% <college< td=""><td>12</td><td>57</td><td>Couples calls</td><td>Diabetes</td><td>HbA Ic,</td><td>4, 8, 12</td></college<>	12	57	Couples calls	Diabetes	HbA Ic,	4, 8, 12
2016, USA					degree				education	DDS and	
					BMI 36					PHQ-9	
Wagner et	107	23	8.5% (69)	6.5 (PAID	Deprived	NR	60	Eight CHW	One 21/2	HbA Ic,	ĸ
al,4° 2016,				short)	Latino			Diabetes	hours group	PAID,	
USA					population.			education+	session	PHQ-9	
					85% <high< td=""><td></td><td></td><td>stress</td><td>diabetes</td><td></td><td></td></high<>			stress	diabetes		
					school			management	education		
Welch et	399	12	9.0% (75)	59vs 51.9	Latino	NR	55	Clinician used	Usual care	HbA Ic,	6
al,48 2015,				control	population			dashboards+		PAID (five-	
USA				(PAID)				educational		item short	
								content+		version),	
								peer support		PHQ-9	
								groups			
Whittemore	53	8	7.7% (61)	42.3	Low	NR	58	Six nurse	Waitlist	HbA Ic,	3, 6
et al, ⁵⁵ 2004,				control	socioeconomic			coaching visits	group design	PAID	
USA				vs 59.9	status						
				(PAID)	BMI 36						
Welch et	234	22	8.9% (74)	42 (PAID)	BMI 35	7	56	Four 30–60	Four 30–60	HbA Ic and	6
al, ⁵⁷ 2011,								minute visits	minutes	PAID	
USA								DSME+ MI	DSME		

duration,⁵⁴ or 2.5-hour diabetes education group sessions,⁴⁹ or 12 one-hour weekly group meetings.⁴⁰

Deliverers

The interventions were delivered by community health workers ethnically matched to patients,^{42,43} nurse case managers,⁵¹ certified diabetes educators^{40,46} in combination with a spouse⁵⁴ or family member,⁵⁰ nurses and dieticians⁴⁸ smartphone applications combined with support from health care providers,⁴⁷ web/telephone,⁴⁴ or telephone.⁵⁴ In five studies, the deliverers were trained in motivational interviewing.^{42,43,51,56,57} The training, fidelity, and quality assessment of delivery were most comprehensively described in interventions using motivational interviewing. In these studies, initial training ranged from 2 days⁵⁷ to 80 hours^{42,51} with ongoing supervision of fidelity by use of validated instruments such as the Behavior Change Counseling Index⁵¹ or the Motivational Interviewing Skills Code.⁵⁷

Risk of bias

We chose to pool all studies in the meta-analysis and provide a narrative description of risk of bias. We judged this approach to be sound as no studies were judged at high risk of selection bias. Moreover, we performed a sensitivity analysis excluding all studies with at least one high risk of bias rating within the remaining domains in the Cochrane Collaboration's risk of bias tool (performance bias, detection bias, attrition bias, reporting bias, and other bias).

Most studies reported sufficient data on random sequence generation and allocation concealment. Gabbay et al⁵¹ moved participants not receiving the intervention to the control group after randomization, resulting in an assessment of high risk of bias. Studies providing comparable enhanced care for control group patients were judged at low risk of performance bias.³⁶ Blinding of outcome assessors was explicitly reported in eight studies and insufficiently described in ten. We judged that insufficient blinding affected self-reported outcomes only. Most studies had inconsistencies between protocol and reported results, for example, insufficient information, nonreporting of specific outcomes due to nonsignificant results. Eight authors were contacted for missing information and one responded.47 Funnel plots were inconclusive due to less than 10 studies in each assessed outcome.37

Diabetes distress

26

DD was a secondary outcome in all 18 studies; 16 of these reported complete results on DD. Tang et al. reported on

selected subscales of the PAID scale only,56 while Welch et al. reported insufficient data.58 Two studies had follow-up at 3, 6, and 12 months;^{45,54} two at 3 and 6 months;^{47,55} one at 6 and 12 months;⁵⁰ and the remaining one single follow-up time point. Meta-analysis of seven studies showed a significant reduction in DD at 3 months follow-up; SMD -0.18 (95% CI -0.32, -0.03), P=0.02 (Figure 2). The quality of the evidence was low due to indirectness and imprecision (Supplementary material S1). Meta-analysis of eight studies showed a significant reduction in DD at 6 months follow-up; SMD -0.20 (95% CI -0.31, -0.08), P=0.006. The quality of the evidence was moderate primarily due to a serious risk of bias. Meta-analysis of six studies showed a significant reduction in DD at 12 months follow-up; SMD -0.21 (95% CI = 0.34, -0.09, P=0.008. The quality of the evidence was moderate due to a serious risk of bias. Meta-analysis of two studies showed a significant reduction in DD at 24 months follow-up; SMD -0.21 (95% CI -0.36, -0.05), P=0.009. The quality of the evidence was low due to very serious risk of bias.

HbAlc

HbA1c was the primary outcome in 16 studies and a secondary outcome in two studies.^{42,50} One study had follow-up at 3, 6, and 12 months;⁵⁴ two at 3 and 6 months;^{47,55} two at 6 and 12 months,^{50,56} and the remaining studies had one follow-up time point.

Meta-analysis of 18 studies showed no significant effect of interventions on HbA1c at any time of follow-up: MD -0.17 (95% CI -0.41, 0.06), P=0.14 at 3 months in six studies (low quality evidence; Figure 3; <u>Supplementary material</u> S2); MD -0.29 (95% CI -0.62, 0.05), P=0.09 at 6 months in nine studies (very low quality evidence); MD 0.02 (95% CI -0.17, 0.22), P=0.84 at 12 months in seven studies (moderate quality evidence); and, MD -0.23 (95% CI -0.50, 0.04), P=0.10 at 24 months in two studies (low quality evidence).

Depression

Depression was a secondary outcome in six studies. Gabbay et al. used the Center for Epidemiologic Studies Depression Scale;⁵¹ five studies used the PHQ-9 scale.^{41,49,52,54,56} Four studies reported results on depression at 3,⁴⁹ 12,⁵⁴ and 24 months.^{51,52} Tang et al merely reported that there was no significant effect on depression.⁵⁶ Sperl-Hillen et al did not provide results that allow mean + SD to be calculated.⁴¹ Meta-analysis of four studies showed an SMD –0.20 (95% CI –0.33, –0.07), *P*=0.003 (forest plot not shown) in favor of the intervention at a mean of 16±10.2 months of follow-up.

	Favours	(interve	ntion)	Stan	dard c	are	5	Std. mean differenc	ce Std. mear	n difference	Risk of bias
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% 0	CI IV, Fixed	l <u>, 95% Cl</u>	ABCDEFG
2.1.1 Diabetes distres	s at 3 mo	nths follo	w-up								
Beverly 2013	27.7	16.9	59	28.9	21.1	60	16.4%	-0.06 (-0.42, 0.30)) —	<u> </u>	••••
Heisler, 2014 (1)	23	28.3	87	30	26.5	89	24.0%	-0.25 (-0.55, 0.04) —	t	
Ing 2016	29.3	20.7	22	26.2	27.5	12	4.3%	0.13 (-0.57, 0.83))	·	??
Kleinman 2017	8.7	3.5	38	10.1	8.4	40	10.7%	-0.21 (-0.66, 0.23)	<u>–</u>	•••••
Trief, 2016	1.6	1.3	97	2	1.3	78	23.5%	-0.31 (-0.61, -0.01) —	1	
Wagner 2016	6.3	6	61	7.4	6.7	46	14.4%	-0.17 (-0.56, 0.21)	-	++?++? +
Whittemore 2004 Subtotal (95% CI)	46.9	19	25 389	44.1	18	24 349	6.7% 100.0%	0.15 (-0.41, 0.71) -0.18 (-0.32, -0.03)			3333 3 3 3
Heterogeneity: χ ² =3.42, c Test for overall effect: Z=2	df=6 (<i>P</i> =0.7 2.37 (<i>P</i> =0.0	'5); <i>I</i> ²=0%)2)									
2.1.2 Diabetes distres	s at 6 mo	nths									
Beverly 2013	26.1	15.3	59	28.3	22.5	62	9.9%	-0.11 (-0.47, 0.24	.) —•	 _	••••
Hermanns 2011	49.1	9.7	85	48	11.2	82	13.7%	0.10 (-0.20, 0.41)		•••?•?•
Kleinman 2017 (2)	8.2	3.1	41	9.3	5	39	6.5%	-0.26 (-0.70, 0.18)	+	$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$
McEwen 2017	9.1	6.6	58	11.6	8.5	54	9.1%	-0.33 (-0.70, 0.05	i) —	t	?????
Spencer 2011 (3)	8.7	13.8	56	12.9	20.3	74	10.4%	-0.23 (-0.58, 0.11)) —	+	??+++?+
Trief, 2016 (4)	1.8	1.2	97	2.2	1.1	78	14.0%	-0.34 (-0.64, -0.04)		$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$
Welch 2015 (5)	40.4	29.6	199	48.3	28.3	200	32.5%	-0.27 (-0.47, -0.08) –		?? •? • ? • •?
Whittemore 2004 (6) Subtotal (95% CI)	46.9	23	25 620	42.9	19	24 613	4.0% 100.0%	0.19 (-0.38, 0.75 -0.20 (-0.31, -0.08) — — — — — — — — — — — — — — — — — — —		?????
Heterogeneity: χ^2 =7.88, c Test for overall effect: Z=3	df=7 (<i>P</i> =0.3 3.44 (<i>P</i> =0.0	4); <i>I</i> ²=11% 0006)	, D								
2.1.3 Diabetes distres	s at 12 m	onths									
Beverly 2013	25	16	58	25.7	22.7	63	12.2%	-0.04 (-0.39, 0.32	.)	-	••••
D'Eramo 2010 (7)	38	16.6	40	47	16.6	37	7.5%	-0.54 (-0.99, -0.08	ý —		• ? • ? • • •
McEwen 2017 (8)	9.9	7	56	10.2	6.6	50	10.7%	-0.04 (-0.43, 0.34) —	<u> </u>	?????
McMahon 2012 (9)	19.2	18.5	51	19.5	14.8	49	10.1%	-0.02 (-0.41, 0.37	·) —	<u> </u>	$\bullet \bullet \bullet \circ \circ$
Sperl-Hillen 2013 (10)	23.3	13.2	489	25.7	13.3	134	42.5%	-0.18 (-0.37, 0.01) -	t	\bullet ? \bullet \bullet \bullet \bullet
Trief, 2016 (11) Subtotal (95% CI)	1.7	1	97 791	2.2	1	78 411	17.0% 100.0%	-0.50 (-0.80, -0.20 -0.21 (-0.34, -0.09	∛		******
Heterogeneity: χ ² =8.11, c Test for overall effect: Z=	if=5 (<i>P</i> =0.1 3.34 (<i>P</i> =0.0	5); <i>l</i> ²=38% 0008)	b								
2.1.4 Diabetes distres	s at 24 m	onths fol	low-up								
Anderson 2009	20.2	18.9	118	22.9	19.9	124	36.9%	-0.14 (-0.39, 0.11) —	+	$\bullet \bullet ? ? \bullet ? ?$
Gabbay 2013 Subtotal (95% CI)	23	21	188 306	29	27	233 357	63.1% 100.0%	-0.24 (-0.44, -0.05			
Heterogeneity: χ^2 =0.43, c Test for overall effect: Z=2	df=1 (<i>P</i> =0.5 2.63 (<i>P</i> =0.0	51); <i>I</i> ²=0% 009)						(· · · ·)	, •		
									<u> </u>		
									-z -1	Eavours (control)	
Test for subgroup differer	nces: χ ² =0.	15, df=3 (<i>l</i>	P=0.98)	; /2=0%					i avours (intervention)		

Figure 2 Meta-analysis: intervention vs standard care on diabetes distress at 3, 6, 12, and 24 months follow-up; (1) Means converted from scale with range 0-100 with positive outcomes reflecting a higher number; (2) 24 weeks follow-up; (3) SDs calculated from Cls using Revman 5.3; (4) Measured DDS at 8 months FU (ITT); (5) SDs calculated from SE using Revman 5.3; (6) Significant difference at baseline; PAID 59,9 intervention group versus 42.3 in the control group; (7) Means+SDs from Cochrane review (Chew et al. 2017); (8) Measured with DDS at 9 months follow-up; (9) online care (intervention) versus web training (control); (10) Means+SDs from Cochrane review (chew et al. 2017); (11) Measured with DDS (ITT). Risk of bias legend: (A) Random sequence generation (selection bias); (B) Allocation concealment (selection bias); (C) Blinding of participants and personnel (performance bias); (D) Blinding of outcome assessment (detection bias); (E) Incomplete outcome data (attrition bias); (F) Selective reporting (reporting bias); (G) Other bias.

The quality of evidence was low due to serious risk of bias (summary of findings table not shown).

shown). The quality of evidence was low due to serious risk of bias and imprecision (summary of findings table not shown).

Health-related quality of life

HRQOL was a secondary outcome in four studies.^{45,46,51,53} Beverly et al measured HRQOL with diabetes QOL at 12 months follow-up,⁴⁵ and Hermanns et al measured HRQOL with SF-12 mental score at 6 months follow-up.⁴⁶ Gabbay et al did not report results due to nonsignificance,⁵¹ while D'Eramo Melkus et al reported on selected subscales of QOL only.⁵³ Meta-analysis of the two studies reporting results on HRQOL showed an SMD of -0.09 (95% CI -0.32, 0.14), *P*=0.46 in favor of the intervention at a mean follow-up of 9 months (forest plot not

Subgroup analysis on DD

Subgroup analysis of studies according to intervention intensity showed a significant reduction in DD of both intensive and brief interventions with the most pronounced effect after intensive intervention; intensive intervention SMD -0.20(95% CI -0.29, -0.11), P<0.001 and brief intervention SMD -0.17 (95% CI -0.32, -0.03), P=0.02. Subgroup analysis of studies according to individual vs group interventions showed a significant reduction in DD of both individual and group interventions with the most pronounced effect after individual

Study or subaroup	Interv Mean	ention SD	Total	Stan Mean	dard c SD	are Total	Weight	Mean difference IV. Random. 95% CI	Mean difference IV. Random, 95% CI	Risk of bias A B C D E F G
1 2 1 HbA1c at 3 mo	nths follo	au-wc						,		
Heisler 2014	7 8	17	87	79	19	89	19 1%	-0 10 (-0 63 0 43)		$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$
Ing 2016	9.3	1.8	22	9.4	27	12	1.9%	-0.10 (-1.80, 1.60)		??.?.?.
Kleinman 2017	79	1.0	44	8.2	1.5	46	17.3%	-0.30 (-0.86, 0.26)		
Trief 2016	8.3	14	97	8.7	1.0	78	28.7%	-0.40(-0.83, 0.03)		
Wagner 2016	8.6	19	70	84	1.6	68	15.8%	0 20 (-0 39 0 79)		••?••?•
Whittemore 2004	73	1	25	74	1	24	17.3%			????.
Subtotal (95% CI)	7.0	•	345	1.4		317	100.0%	-0.17(-0.41, 0.06)	•	
Heterogeneity: $\tau^2=0$ ($0. \gamma^2 = 2$	95 df=	=5 (P=	0 71) 6	² =0%	017	100.070	0.17 (0.41, 0.00)		
Test for overall effect:	Z=1.46	(<i>P</i> =0.1	14)	0.1 1), 1	070					
1.2.2 HbA1c at 6 mor	nths follo	w-up								
Hermanns 2011	7.9	1.2	85	7.8	1.5	82	11.9%	0.10 (-0.31, 0.51)		•••?•?•
Kleinman 2017	7.9	1.1	44	8.2	1.5	46	10.6%	-0.30 (-0.84, 0.24)		$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$
McEwen 2017	8.9	1.8	58	9.5	19	54	9.1%	-0.60 (-1.29, 0.09)		???????
Spencer 2011 (1)	7.8	1.9	56	8.5	2.3	57	8.2%	-0.70 (-1.48, 0.08)		??+++?+
Tang 2013	7.9	1.39	193	8.6	1.94	189	12.7%	-0.70 (-1.04, -0.36)	_ _	$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$
Trief, 2016 (2)	8.5	1.5	97	8.7	1.4	78	11.7%	-0.20 (-0.63, 0.23)		$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$
Welch 2011a (3)	8.6	1.35	90	8.1	1.29	94	12.2%	0.50 (0.12, 0.88)	_ _	?? • ? • • •
Welch 2015 (4)	8.4	1.4	200	9.2	1.4	199	13.3%	-0.80 (-1.07, -0.53)		?? +? + ??
Whittemore 2004	7.5	1	25	7.5	1	24	10.4%	0.00 (-0.56, 0.56)		?????
Subtotal (95% CI)			848			823	100.0%	–0.29 (–0.62, 0.05)	-	
Heterogeneity: $\tau^2=0.2$ Test for overall effect:	20; χ ² =4΄ Z=1.68	1.27, d (<i>P</i> =0.0	f=8 (<i>P</i> 09)	<0.0000)1); <i> </i> ²=	81%				
1 2 3 HbA1c at 12 m	onths fol	low-un								
Beverly 2013 (5)	8 54	14	58	8 1	1	63	14 7%	0.44 (0.00 0.88)		
D'Framo 2010	7 2	22	40	8	24	37	3.3%			
McEwen 2017 (6)	9.2	21	56	92	2	50	5.6%	0.00 (-0.78, 0.78)		2222020
McMahon 2012	8.3	1.1	51	8.4	1.7	49	9.8%	-0.10 (-0.66, 0.46)		•••?•?•
Sperl-Hillen 2013 (7)	7.8	12	489	77	12	134	31.8%	0 10 (-0 13 0 33)		
Tang 2013	8.1	1.68	186	8.3	1.81	193	19.9%	-0.20 (-0.55, 0.15)		
Trief 2016 (8)	8.5	1.5	97	8.5	1.4	78	15.0%	0.00 (-0.43, 0.43)	-+	$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$
Subtotal (95% CI)			977			604	100.0%	0.02 (–0.17, 0.21)	•	
Heterogeneity: $\tau^2=0.0$ Test for overall effect:)2; χ ² =8. Z=0.20	10, df= (<i>P</i> =0.8	=6 (<i>P</i> = 34)	0.23); <i>ĺ</i>	2=26%					
1.2.4 HbA1c at 24 mo	onths fol	low-up								
Anderson 2009	7.62	1.8	122	7.91	2.03	126	33.1%	-0.29 (-0.77, 0.19)		$\bullet \bullet ? ? \bullet ? ?$
Gabbay 2013 Subtotal (95% CI)	7.8	1.7	188 310	8	1.8	233 359	66.9% 100.0%	-0.20 (-0.54, 0.14) -0.23 (-0.50, 0.04)		
Heterogeneity: $\tau^2=0.0$ Test for overall effect:	0; χ ² =0. Z=1.64	09, df= (<i>P</i> =0.1	=1 (<i>P</i> = 10)	0.76); <i>ĺ</i>	² =0%			,		
								-		4
								_	Intervention Standard care	
Test for subgroup diff	erences	$\chi^2 = 3.$	78, df=	=3 (P=0	.29); l ²	=20.6	%			

Figure 3 Meta-analysis: intervention vs standard care on HbA1c at 3, 6, 12, and 24 months follow-up; (1) SDs calculated from Cl using Revman 5.3; (2) At 8 months followup (ITT); (3) Mean+SDs calculated from within group differences; (4) SDs Calculated from SE using Revman 5.3; (5) Mean+SDs from Cochrance review (Chew et al. 2017); (6) At 9 months follow-up; (7) Means+SDs from Cochrance review (Chew et al. 2017); (8) ITT; Risk of bias legend; (A) Random sequence generation (selection bias); (B) Allocation concealment (selection bias); (C) Blinding of participants and personnel (performance bias); (D) Blinding of outcome assessment (detection bias); (E) Incomplete

intervention; SMD -0.25 (95% CI -0.36, -0.14), P<0.001 vs SMD -0.13 (-0.24, -0.02), P=0.02. Subgroup analysis of the three studies incorporating motivational interviewing showed a significant reduction in favor of motivational interviewing; SDM -0.25 (95% CI -0.39, -0.10), P=0.001 (Supplementary material S3; subgroup analyses DD).

outcome data (attrition bias); (F) Selective reporting (reporting bias); (G) Other bias

Subgroup analysis on HbAIc

Meta-analysis of studies according to intervention intensity showed a reduction in HbA1c after intensive interventions, but deterioration after brief interventions; MD -0.23 (95% CI -0.44, -0.01), *P*=0.04 and MD 0.15 (95% CI -0.11, 0.40), *P*=0.26, respectively. Meta-analysis of studies according to individual vs group showed a reduction in HbA1c of individual, but not group intervention; MD –0.15 (95% CI –0.45, 0.15), P=0.34 and MD 0.02 (95% CI –0.18, 0.21), P=0.86, respectively. Meta-analysis of studies according to use of motivational interviewing showed a reduction of –0.08 (95% CI –0.43, 0.26), P=0.63 in favor of motivational interviewing (Supplementary material S4).

Sensitivity analysis

Removing six studies at high risk of attrition bias^{40,47,49,51–53} did not significantly change estimates of intervention effects on DD: SMD -0.25 (95% CI -0.55, 0.04) *P*=0.09 at 3 months, SMD -0.19 (95% CI -0.31, -0.08) *P*=0.001 at 6 months, and

28

at 12 months, SMD -0.19 (95% CI -0.32, -0.06) *P*=0.005. Removing studies with at least one high risk of bias rating reduced effect estimates at 6 months, SMD -0.15 (95% CI -0.33, 0.03) *P*=0.10 and at 24 months, SMD -0.14 (95% CI -0.39, 0.11) *P*=0.28, while the effect estimates increased at 3 months, SMD -0.26 (95% CI -0.44, 0.07) *P*=0.007 and at 12 months, SMD -0.23 (95% CI -0.38, -0.09) *P*=0.002.

Discussion

This review provided low to moderate quality evidence for small significant reductions in DD over time and very low to moderate quality evidence for no effect on HbA1c of psychosocial interventions. We found low quality evidence for a small reduction in depression, and moderate quality evidence for no effect on HRQOL.

The effect on DD was small (SMD < 0.40);²⁵ nevertheless, it may reflect a clinically significant improvement in a highrisk population disproportionately affected by a clustering of risk factors and ensuing high risk of diabetes complications.^{8,59} The most distressed persons are also more likely to have high blood pressure⁶⁰ and high LDL cholesterol,⁵ both factors equally important as HbA1c for prevention of microand macrovascular complications.⁶¹ There is evidence for an association between DD and adherence to medication.5,18 Reducing DD and thereby increasing treatment adherence might be an intermediate pathway to preventing diabetes complications in this population. In a review also focusing on cognition- and emotion-focused interventions, Chew et al reported nonsignificant reductions in DD in a general population with T2DM.20 Our findings indicate that vulnerable people with T2DM might benefit proportionately more from psychosocial interventions targeting DD.

The reduction in DD was not accompanied by a reduction in HbA1c. This opposed to Fisher et al,¹² who reported a significant association between reduced DD and improved glycemic control during 18 months follow-up in a general T2DM population. Chew et al. reported a borderline significant effect on HbA1c, but as previously mentioned, no effect on DD.²⁰

The conflicting findings might be explained by the vulnerability criteria applied in this review including one or more comorbidities⁶² and longer duration of diabetes²³ which, pathophysiologically⁶³ and mentally, might hamper possible effects of interventions on HbA1c despite reduced levels of DD. From an equity perspective, people with low socioeconomic status, low health literacy, and diabetes-related sequelae may profit less from interventions, in spite of efforts to tailor interventions to their particular needs.⁶⁴

Hypothetically, not all interventions in included studies were optimally customized to this specific population. Furthermore, vulnerability may affect adherence to interventions in clinical trials.⁶⁵ An implication of our findings could be stratified interventions for patients with low health literacy, social problems, and language and logistic barriers. This could accommodate access, attendance, and integration of interventions and potentially reduce attrition in this group of patients. Stratified interventions would likely require training of health care professionals in culturally and literacy sensitive aspects of person-centered diabetes care.

The lacking effect on HbA1c lends support to previous research suggesting a noncausal link between DD and HbA1c.¹³ However, provision of preintervention to all participants prior to randomization in three studies^{40,49,54} and enhanced standard care to control groups in eleven studies^{40,42,44-47,49,52-54,58} might also have played a role. Previous trials have moreover suggested that behavioral interventions may be more effective in people with a poorer baseline psychological state,66 while other studies link their effectiveness to having intervened on people with HbA1c≥9.0% (75 mmol/ mol).⁶⁷ Indeed, the baseline levels of both DD (mean 39 ± 10.8) and HbA1c 8.7% (mean 72±7.7) were clinically important in the studies included.⁶⁸ Preinterventions and enhanced standard care may, however, have weakened the level to which DD and HbA1c could be reduced. This explanation is supported by the weaker effect of interventions at 3 months compared with 6 months contradictory to the well-established Hawthorne effect.69

There was low quality evidence from four studies for a small but significant reduction in depression. This lends support to the suggested link between depression and DD⁹ and may have clinical potential if there is an association between reduced depression and improved diabetes self-management, as previously reported.¹⁸ Our results may, however, reflect the instruments used to measure depression in included studies. According to Fisher et al, depression should be assessed using a gold standard structured clinical interview.¹¹ Preferably, this approach should be used uniformly to distinguish depression from DD and direct care effectively.¹¹ Despite the heterogeneous instruments used, studies have reported a disproportionate burden of depression in people with T2DM.⁷⁰ Similar to our findings, other studies also failed to identify improvements in glycemic control despite reduction in depression.13,71

Exploratory subgroup analysis indicated a deteriorating effect of brief interventions on HbA1c. This could indicate that vulnerable people with T2DM benefit less from brief

interventions, perhaps because they lack individualized peer support.⁷² This points toward a need for continuity and a designated health care professional as proposed in other studies.^{73,74} The explorative subgroup analyses of effects on DD of individual vs group and intensive vs brief interventions endorse this interpretation.

Subgroup analysis of interventions incorporating motivational interviewing indicated a potential association with reduced DD. Again, this effect did not "spill over" on HbA1c, although it should be noted that only one of the studies included in the analysis identified an increase in HbA1c.⁵⁷ This study tested a brief intervention and was at high risk of bias, primarily due to attrition (35%).⁵⁷

Our results lend support to the relevance of further research on person-centered care such as motivational interviewing for reducing DD, and increasing glycemic control in vulnerable people with T2DM.²¹ Diverse theoretical foundations determined the content of interventions. Notwithstanding the value of theoretically founded interventions, there is some concern about a potential gap between theory and the implementation of person-centered care in clinical practice.⁷⁵ If interventions do not sufficiently reflect the theoretical foundation, effect may be weakened. Our review nevertheless adds further to the potential promise of person-centered care, eg, motivational interviewing including person-centered support from a devoted person for vulnerable people with T2D. Such approaches should consider the patients' everyday life including their social network and life values.

Strengths and limitations

This review adhered to the Cochrane Collaboration's methodology for systematic reviews to rigorously examine the evidence for an effect of psychosocial interventions vs standard care on DD and, secondly, on HbA1c, depression, and HRQOL in vulnerable people with T2DM. Nonetheless, several factors might have influenced effect estimates.

We applied the SMD on outcomes where studies used different instruments for measuring DD, depression, and HRQOL. The application of the SMD has, however, been reported to be inaccurate and even erroneous⁷⁶ due to data extraction errors, mistakes in calculations, or confusion regarding the direction of the included scales for specific outcomes. To avoid these pitfalls, our data extraction process was performed twice by each reviewer to ensure accuracy. Moreover, we used Review Manager to perform calculations and chose to include only studies using validated instruments (PAID and DDS).

Secondly, sensitivity analysis revealed that removing studies with high risk of bias reduced effect estimates on DD at 6 and 24 months follow-up, while they increased at 3 and 12 months. The results remained statically significant at 3 and 12 months follow-up only. This differs from the findings of Savovic et al, who concluded that low quality studies are more likely to report large effect sizes.⁷⁷ Removing studies with high attrition marginally attenuated effect estimates on DD. This might indicate a minor overestimation of effect sizes due to high attrition. However, the effect on DD at 6 and 12 months remained statistically significant.

Thirdly, poor reporting of results and missing information resulted in an assessment of most studies as being at "unclear" risk of bias. Likewise, in studies with insufficient reporting, some authors stated that lack of reported results was due to nonsignificant differences between groups at follow-up.⁵⁶ Consequently, studies showing no increase or decrease in outcomes were not included in meta-analyses, potentially leading to overestimation of effects. Inclusion of a wait-list design in three studies might have induced anticipation bias and reduced between-group differences at follow-up. Moreover, the use of available case analysis may have augmented the effect on all outcomes.

Baseline DD values differed significantly between the intervention and the control groups in four studies.^{47,48,55,44} Due to nonreporting of change scores in eleven studies.^{41,45,47–51,53–56} and the use of different instruments for measuring DD, we considered that post hoc exploratory analyses using available change scores would be misleading.²⁵ Moreover, imbalance between groups at baseline should be eliminated in meta-analysis.³⁶

If the effects of emotion- vs cognition-based interventions could be distinguished, it might have strengthened the review. However, some of the most cited theoretical models underlying the interventions, eg, Bandura's model on self-efficacy,^{30,31} involve both emotion- and cognition-based constructs. Therefore, we were unable to distinguish effects of interventions according to underlying theory. The generalizability of our findings might be limited by the inclusion of only two studies originating from other countries than United States.

Conclusion

We found low to moderate quality evidence for a significant, but small reduction in DD and very low to moderate quality evidence for no effect on HbA1c at 3, 6, 12, and 24 months follow-up of psychosocial interventions. The reduction in depression was significant, but small, while there was no effect on HRQOL. Exploratory subgroup analyses showed significant incremental reductions in DD and HbA1c of intensive (>4 sessions) vs brief interventions. On HbA1c, there was a nonsignificant trend toward deteriorating HbA1c

30

after brief intervention. Individual and group interventions significantly reduced DD, but not HbA1c. On both outcomes the largest reductions were found after individual interventions. Subgroup analysis of interventions using motivational interviewing was associated with larger effects on DD, but not on HbA1c.

Acknowledgments

This review was funded by the University Hospital of Copenhagen, Rigshospitalet, grant number E-22260-04, Denmark, TRYG Foundation, Denmark, Grant number 103925, The Novo Nordisk Foundation, Denmark, Grant Number 6265, and the Lundbeck Foundation, Denmark. The funding sources had no role in any stage of the research process.

Author contributions

Literature searches were performed by ASM. The initial screening of title and abstract, including full-text screening, was performed by ASM and TT. Data from studies eligible for inclusion were extracted and bias assessed by ASM and GK with disagreement solved by IE or TT. Meta-analyses and GRADE assessments were conducted by ASM and TT. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

- Polonsky WH, Anderson BJ, Lohrer PA, et al. Assessment of diabetesrelated distress. *Diabetes Care*. 1995;18(6):754–760.
- Lipscombe C, Burns RJ, Schmitz N. Exploring trajectories of diabetes distress in adults with type 2 diabetes; a latent class growth modeling approach. J Affect Disord. 2015;188:160–166.
- Fisher L, Skaff MM, Mullan JT, Arean P, Glasgow R, Masharani U. A longitudinal study of affective and anxiety disorders, depressive affect and diabetes distress in adults with Type 2 diabetes. *Diabet Med.* 2008;25(9):1096–1101.
- Stoop CH, Nefs G, Pop VJ, et al. Diabetes-specific emotional distress in people with Type 2 diabetes: a comparison between primary and secondary care. *Diabet Med.* 2014;31(10):1252–1259.
- Pandit AU, Bailey SC, Curtis LM, et al. Disease-related distress, selfcare and clinical outcomes among low-income patients with diabetes. *J Epidemiol Community Health*. 2014;68(6):557–564.
- Hessler D, Fisher L, Glasgow RE, et al. Reductions in regimen distress are associated with improved management and glycemic control over time. *Diabetes Care*. 2014;37(3):617–624.
- Zulman DM, Rosland AM, Choi H, Langa KM, Heisler M. The influence of diabetes psychosocial attributes and self-management practices on change in diabetes status. *Patient Educ Couns*. 2012;87(1):74–80.
- Kasteleyn MJ, de Vries L, van Puffelen AL, et al. Diabetes-related distress over the course of illness: results from the Diacourse study. *Diabet Med.* 2015;32(12):1617–1624.

- Burns RJ, Deschênes SS, Schmitz N. Cyclical relationship between depressive symptoms and diabetes distress in people with Type 2 diabetes mellitus: results from the Montreal Evaluation of Diabetes Treatment Cohort Study. *Diabet Med.* 2015;32(10):1272–1278.
- Park M, Katon WJ, Wolf FM. Depression and risk of mortality in individuals with diabetes: a meta-analysis and systematic review. *Gen Hosp Psychiatry*. 2013;35(3):217–225.
- Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. *Diabet Med*. 2014;31(7):764–772.
- Fisher L, Glasgow RE, Strycker LA. The relationship between diabetes distress and clinical depression with glycemic control among patients with type 2 diabetes. *Diabetes Care*. 2010;33(5):1034–1036.
- Fisher L, Mullan JT, Arean P, Glasgow RE, Hessler D, Masharani U. Diabetes distress but not clinical depression or depressive symptoms is associated with glycemic control in both cross-sectional and longitudinal analyses. *Diabetes Care*. 2010;33(1):23–28.
- Shivayogi P. Vulnerable population and methods for their safeguard. Perspect Clin Res. 2013;4(1):53–57.
- Walker RJ, Smalls BL, Egede LE. Social determinants of health in adults with type 2 diabetes--contribution of mutable and immutable factors. *Diabetes Res Clin Pract*. 2015;110(2):193–201.
- Cutrona CE, Abraham WT, Russell DW, et al. Financial strain, inflammatory factors, and haemoglobin A1c levels in African American women. *Br J Health Psychol.* 2015;20(3):662–679.
- Wardian JL, Tate J, Folaron I, Graybill S, True M, Sauerwein T. Who's distressed? A comparison of diabetes-related distress by type of diabetes and medication. *Patient Educ Couns*. 2018;101(8):1490–1495.
- Aikens JE. Prospective associations between emotional distress and poor outcomes in type 2 diabetes. *Diabetes Care*. 2012;35(12):2472–2478.
- Dennick K, Sturt J, Speight J. What is diabetes distress and how can we measure it? A narrative review and conceptual model. *J Diabetes Complications*. 2017;31(5):898–911.
- Chew BH, Vos RC, Metzendorf MI, Scholten RJ, Rutten GE. Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2017;9:CD011469.
- Sturt J, Dennick K, Hessler D, Hunter BM, Oliver J, Fisher L. Effective interventions for reducing diabetes distress: systematic review and meta-analysis. *Int Diab Nurs*. 2015;12(2):40–55.
- Fisher L, Hessler DM, Polonsky WH, Mullan J. When is diabetes distress clinically meaningful?: establishing cut points for the Diabetes Distress Scale. *Diabetes Care*. 2012;35(2):259–264.
- Lamers F, Jonkers CC, Bosma H, Knottnerus JA, van Eijk JT. Treating depression in diabetes patients: does a nurse-administered minimal psychological intervention affect diabetes-specific quality of life and glycaemic control? A randomized controlled trial. JAdv Nurs. 2011;67(4):788–799.
- Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015;349:g7647.
- Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Vol 5.1.0: London, UK: The Cochrane Collaboration; 2011.
- Dagogo-Jack S. Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management. *J Natl Med Assoc*. 2003;95(9):774–789.
- O'Neill J, Tabish H, Welch V, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. *J Clin Epidemiol*. 2014;67(1):56–64.
- Chiang JL, Kirkman MS, Laffel LM, Peters AL, Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. *Diabetes Care*. 2014;37(7):2034–2054.
- Chew BH, Shariff-Ghazali S, Fernandez A. Psychological aspects of diabetes care: effecting behavioral change in patients. *World J Diabetes*. 2014;5(6):796–808.
- Bandura A, Adams NE, Beyer J. Cognitive processes mediating behavioral change. J Pers Soc Psychol. 1977;35(3):125–139.

- Bandura A, Cioffi D, Taylor CB, Brouillard ME. Perceived self-efficacy in coping with cognitive stressors and opioid activation. J Pers Soc Psychol. 1988;55(3):479–488.
- Polonsky WH, Fisher L, Earles J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. *Diabetes Care*. 2005;28(3):626–631.
- Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in diabetes: time for an appraisal. *Lancet Diabetes Endocrinol*. 2015;3(6):450–460.
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613.
- 35. Covidence Systematic Review Software. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available from: www.covidence.org. Accessed November 16, 2018.
- Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
- Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ*. 2011;343:d4002.
- Ritzwoller DP, Sukhanova AS, Glasgow RE, et al. Intervention costs and cost-effectiveness for a multiple-risk-factor diabetes self-management trial for Latinas: economic analysis of ¡Viva Bien! *Transl Behav Med*. 2011;1(3):427–435.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924–926.
- Ing CT, Zhang G, Dillard A, et al. Social support groups in the maintenance of glycemic control after community-based intervention. J Diabetes Res. 2016;2016:7913258-8.
- Sperl-Hillen J, Beaton S, Fernandes O, et al. Are benefits from diabetes self-management education sustained? *Am J Manag Care*. 2013;19(2):104–112.
- 42. Heisler M, Choi H, Palmisano G, et al. Comparison of community health worker-led diabetes medication decision-making support for low-income Latino and African American adults with diabetes using e-health tools versus print materials: a randomized, controlled trial. *Ann Intern Med.* 2014;161(10 Suppl):S13–S22.
- Spencer MS, Rosland AM, Kieffer EC, et al. Effectiveness of a community health worker intervention among African American and Latino adults with type 2 diabetes: a randomized controlled trial. *Am J Public Health*. 2011;101(12):2253–2260.
- 44. Mcmahon GT, Fonda SJ, Gomes HE, Alexis G, Conlin PR. A randomized comparison of online- and telephone-based care management with internet training alone in adult patients with poorly controlled type 2 diabetes. *Diabetes Technol Ther*. 2012;14(11):1060–1067.
- Beverly EA, Fitzgerald SM, Brooks KM, et al. Impact of reinforcement of diabetes self-care on poorly controlled diabetes: a randomized controlled trial. *Diabetes Educ*. 2013;39(4):504–514.
- Hermanns N, Kulzer B, Maier B, Mahr M, Haak T. The effect of an education programme (MEDIAS 2 ICT) involving intensive insulin treatment for people with type 2 diabetes. *Patient Educ Couns*. 2012;86(2):226–232.
- 47. Kleinman NJ, Shah A, Shah S, Phatak S, Viswanathan V. Improved medication adherence and frequency of blood glucose self-testing using an m-Health Platform Versus usual care in a multisite randomized clinical trial among people with type 2 diabetes in India. *Telemed J E Health*. 2017;23(9):733–740.
- Welch G, Zagarins SE, Santiago-Kelly P, et al. An internet-based diabetes management platform improves team care and outcomes in an urban Latino population. *Diabetes Care*. 2015;38(4):561–567.
- 49. Wagner JA, Bermudez-Millan A, Damio G, et al. A randomized, controlled trial of a stress management intervention for Latinos with type 2 diabetes delivered by community health workers: outcomes for psychological wellbeing, glycemic control, and cortisol. *Diabetes Res Clin Pract.* 2016;120:162–170.

- Mcewen MM, Pasvogel A, Murdaugh C, Hepworth J. Effects of a familybased diabetes intervention on behavioral and biological outcomes for Mexican American adults. *Diabetes Educ*. 2017;43(3):272–285.
- 51. Gabbay RA, Añel-Tiangco RM, Dellasega C, Mauger DT, Adelman A, van Horn DH. Diabetes nurse case management and motivational interviewing for change (DYNAMIC): results of a 2-year randomized controlled pragmatic trial. *J Diabetes*. 2013;5(3):349–357.
- Anderson RM, Funnell MM, Aikens JE, et al. Evaluating the efficacy of an empowerment-based self-management consultant intervention: results of a two-year randomized controlled trial. *Ther Patient Educ*. 2009;1(1):3–11.
- 53. D'Eramo Melkus G, Chyun D, Vorderstrasse A, Newlin K, Jefferson V, Langerman S. The effect of a diabetes education, coping skills training, and care intervention on physiological and psychosocial outcomes in black women with type 2 diabetes. *Biol Res Nurs*. 2010;12(1):7–19.
- 54. Trief PM, Fisher L, Sandberg J, et al. Health and psychosocial outcomes of a telephonic couples behavior change intervention in patients with poorly controlled type 2 diabetes: a randomized clinical trial. *Diabetes Care*. 2016;39(12):2165–2173.
- Whittemore R, Melkus GD, Sullivan A, Grey M. A nurse-coaching intervention for women with type 2 diabetes. *Diabetes Educ*. 2004;30(5):795–804.
- 56. Tang PC, Overhage JM, Chan AS, et al. Online disease management of diabetes: engaging and motivating patients online with enhanced resources-diabetes (EMPOWER-D), a randomized controlled trial. J Am Med Inform Assoc. 2013;20(3):526–534.
- Welch G, Zagarins SE, Feinberg RG, Garb JL. Motivational interviewing delivered by diabetes educators: does it improve blood glucose control among poorly controlled type 2 diabetes patients? *Diabetes Res Clin Pract.* 2011;91(1):54–60.
- Welch G, Allen NA, Zagarins SE, Stamp KD, Bursell SE, Kedziora RJ. Comprehensive diabetes management program for poorly controlled Hispanic type 2 patients at a community health center. *Diabetes Educ.* 2011;37(5):680–688.
- Larrañaga I, Arteagoitia JM, Rodriguez JL, et al. Socio-economic inequalities in the prevalence of Type 2 diabetes, cardiovascular risk factors and chronic diabetic complications in the Basque Country, Spain. *Diabet Med.* 2005;22(8):1047–1053.
- 60. Chew BH, Sherina MS, Hassan NH. Association of diabetes-related distress, depression, medication adherence, and health-related quality of life with glycated hemoglobin, blood pressure, and lipids in adult patients with type 2 diabetes: a cross-sectional study. *Ther Clin Risk Manag.* 2015;11:669–681.
- 61. Oellgaard J, Gæde P, Rossing P, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. *Diabetologia*. 2018;61(8):1724–1733.
- 62. Chiu CJ, Yh H, Wray LA. Dissemination of evidence-base minimal psychological intervention for diabetes management in Taiwan adults with type 2 diabetes. *Int J Clin Exp Med.* 2016;9(7):14489–14498.
- 63. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998;352(9131):837–853.
- 64. Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes outcomes. *JAMA*. 2002;288(4):475–482.
- Maindal HT, Skriver MV, Kirkevold M, Lauritzen T, Sandbaek A. Comorbidity and lack of education countered participation in a diabetes prevention self-management program. *J Nurs Healthc Chronic Illn.* 2011;3(3):293–301.
- Robertson SM, Amspoker AB, Cully JA, Ross EL, Naik AD. Affective symptoms and change in diabetes self-efficacy and glycaemic control. *Diabet Med.* 2013;30(5):e189–e196.
- Health Quality Ontario. Behavioural Interventions for type 2 diabetes: an evidence-based analysis. *Ont Health Technol Assess Ser*. 2009;9(21):1–45.

32

- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med Overseas Ed.* 2008;359(15):1577–1589.
- Mccarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. *BMC Med Res Methodol*. 2007;7(1):30.
- Naranjo DM, Fisher L, Areán PA, Hessler D, Mullan J. Patients with type 2 diabetes at risk for major depressive disorder over time. *Ann Fam Med.* 2011;9(2):115–120.
- Williams JW, Katon W, Lin EH, et al. The effectiveness of depression care management on diabetes-related outcomes in older patients. *Ann Intern Med.* 2004;140(12):1015–1024.
- Sokol R, Fisher E. Peer support for the hardly reached: a systematic review. *Am J Public Health*. 2016;106(7):e1–e8.
- Torenholt R, Varming A, Engelund G, et al. Simplicity, flexibility, and respect: preferences related to patient education in hardly reached people with type 2 diabetes. *Patient Prefer Adherence*. 2015;9:1581–1586.

- 74. Mathiesen AS, Thomsen T, Jensen T, Schiøtz C, Langberg H, Egerod I. The influence of diabetes distress on digital interventions for diabetes management in vulnerable people with type 2 diabetes: a qualitative study of patient perspectives. J Clin Transl Endocrinol. 2017;9:41–47.
- Zoffmann V, Hörnsten Å, Storbækken S, et al. Translating personcentered care into practice: a comparative analysis of motivational interviewing, illness-integration support, and guided self-determination. *Patient Educ Couns*. 2016;99(3):400–407.
- Gøtzsche PC, Hróbjartsson A, Marić K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. *JAMA*. 2007;298(4):430–437.
- Savovic J, Turner RM, Mawdsley D. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES Meta-Epidemiologic Study. *Am J Epidemiol.* 2018;187(5):1113–1122.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

33

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal